• 1
    Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F. et al., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008. 26: 52335239.
  • 2
    Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2011. 363: 711723.
  • 3
    Robert, C., Thomas, L., Bondarenko, I., O'Day, S., M, D. J., Garbe, C., Lebbe, C., Baurain, J. F. et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011. 364: 251726.
  • 4
    Rosenberg, S. A., Yang, J. C. and Restifo, N. P., Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004. 10: 909915.
  • 5
    Eggermont, A. M., Immunotherapy: vaccine trials in melanoma – time for reflection. Nat. Rev. Clin. Oncol. 2009. 6: 256258.
  • 6
    Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., Atkins, M. B. et al., Defining the critical hurdles in cancer immunotherapy. J. Transl. Med. 2011. 9: 214.
  • 7
    Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C. and Speiser, D. E., The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012. 33: 364372.
  • 8
    Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P. and Bachmann, M. F., Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008. 38: 14041413.
  • 9
    Hofbauer, G. F., Kamarashev, J., Geertsen, R., Boni, R. and Dummer, R., Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998. 8: 337343.
  • 10
    Speiser, D. E., Schwarz, K., Baumgaertner, P., Manolova, V., Devevre, E., Sterry, W., Walden, P. et al., Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J. Immunother. 2010. 33: 848858.
  • 11
    Braun, M., Jandus, C., Maurer, P., Hammann-Haenni, A., Schwarz, K., Bachmann, M. F., Speiser, D. E. et al., Virus-like particles induce robust human T-helper cell responses. Eur. J. Immunol. 2012. 42: 330340.
  • 12
    Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillaume, P., Luescher, I. F., Lienard, D., Lejeune, F. et al., Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 2003. 13: 461472.
  • 13
    Appay, V., Speiser, D. E., Rufer, N., Reynard, S., Barbey, C., Cerottini, J. C., Leyvraz, et al., Decreased specific CD8+ T-cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur. J. Immunol. 2006. 36: 18051814.
  • 14
    Fourcade, J., Kudela, P., Andrade Filho, P. A., Janjic, B., Land, S. R., Sander, C., Krieg, A. et al., Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother. 2008. 31: 781791.
  • 15
    Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M. et al., Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008. 181: 776784.
  • 16
    Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G. and Gilliet, M., Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 2005. 97: 11431153.
  • 17
    Speiser, D. E., Pittet, M. J., Guillaume, P., Lubenow, N., Hoffman, E., Cerottini, J. C. and Romero, P., Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J. Immunother. 2004. 27: 298308.
  • 18
    Baumgaertner, P., Jandus, C., Rivals, J. P., Derre, L., Lovgren, T., Baitsch, L., Guillaume, P. et al., Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer 2012. 130: 26072617.
  • 19
    Posnett, D. N., Engelhorn, M. E., Lin, Y., Merghoub, T., Duan, F., Wolchok, J. D. and Houghton, A. N., Development of effective vaccines for old mice in a tumor model. Vaccine 2009. 27: 10931100.
  • 20
    Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A., Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999. 401: 708712.
  • 21
    Bouwhuis, M. G., Ten Hagen, T. L., Suciu, S. and Eggermont, A. M., Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol. 2011. 23: 170176.
  • 22
    Chianese-Bullock, K. A., Pressley, J., Garbee, C., Hibbitts, S., Murphy, C., Yamshchikov, G., Petroni, G. R. et al., MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol. 2005. 174: 30803086.
  • 23
    Lienard, D., Rimoldi, D., Marchand, M., Dietrich, P. Y., van Baren, N., Geldhof, C., Batard, P. et al., Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004. 4: 4.
  • 24
    Heinzerling, L. M., Anliker, M. D., Muller, J., Schlaeppi, M. and von Moos, R., Sarcoidosis induced by interferon-α in melanoma patients: incidence, clinical manifestations, and management strategies. J. Immunother. 33: 834839.
  • 25
    Bachmann, M. F. and Jennings, G. T., Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010. 10: 787796.
  • 26
    Speiser, D. E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A. M. et al., Rapid and strong human CD8+ T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005. 115: 739746.
  • 27
    Gattinoni, L., Zhong, X. S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C. et al., Wnt signaling arrests effector T-cell differentiation and generates CD8+ memory stem cells. Nat. Med. 2009. 15: 808813.
  • 28
    Araki, K., Youngblood, B. and Ahmed, R., The role of mTOR in memory CD8 T-cell differentiation. Immunol. Rev. 2010. 235: 234243.
  • 29
    Finlay, D. and Cantrell, D. A., Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 2011. 11: 109117.
  • 30
    Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R. et al., Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011. 470: 543547.
  • 31
    Bins, A., Mallo, H., Sein, J., van den Bogaard, C., Nooijen, W., Vyth-Dreese, F., Nuijen, B. et al., Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J. Immunother. 2007. 30: 234239.
  • 32
    Butterfield, L. H., Comin-Anduix, B., Vujanovic, L., Lee, Y., Dissette, V. B., Yang, J. Q., Vu, H. T. et al., Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother. 2008. 31: 294309.
  • 33
    Chakraborty, N. G., Chattopadhyay, S., Mehrotra, S., Chhabra, A. and Mukherji, B., Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 2004. 65: 794802.
  • 34
    Di Pucchio, T., Pilla, L., Capone, I., Ferrantini, M., Montefiore, E., Urbani, F., Patuzzo, R. et al., Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 2006. 66: 49434951.
  • 35
    Lesimple, T., Neidhard, E. M., Vignard, V., Lefeuvre, C., Adamski, H., Labarriere, N., Carsin, A. et al., Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin. Cancer Res. 2006. 12: 73807388.
  • 36
    Ribas, A., Weber, J. S., Chmielowski, B., Comin-Anduix, B., Lu, D., Douek, M., Ragavendra, N. et al., Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin. Cancer Res. 2011. 17: 29872996.
  • 37
    Tuettenberg, A., Becker, C., Huter, E., Knop, J., Enk, A. H. and Jonuleit, H., Induction of strong and persistent Melan A/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int. J. Cancer 2006. 118: 26172627.
  • 38
    Weber, J., Boswell, W., Smith, J., Hersh, E., Snively, J., Diaz, M., Miles, S. et al., Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 2008. 31: 215223.
  • 39
    Speiser, D. E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N. and Romero, P., Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 2008. 105: 38493854.
  • 40
    Panagiotidis, E., Exarhos, D., Housianakou, I., Bournazos, A. and Datseris, I., FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1). Eur. Radiol. 2010. 20: 12511253.
  • 41
    Thomassen, A., Lerberg Nielsen, A., Gerke, O., Johansen, A. and Petersen, H., Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination. Eur. J. Nucl. Med. Mol. Imaging 2011. 38: 894898.
  • 42
    Burger, I. A., Husmann, L., Hany, T. F., Schmid, D. T. and Schaefer, N. G., Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin. Nucl. Med. 2011. 36: 848853.
  • 43
    Williams, G., Joyce, R. M. and Parker, J. A., False-+ axillary lymph node on FDG-PET/CT scan resulting from immunization. Clin. Nucl. Med. 2006. 31: 731732.
  • 44
    Sheehy, N. and Drubach, L., (18)F-FDG uptake at vaccination site. Pediatr. Radiol. 2008. 38: 246.
  • 45
    Iyengar, S., Chin, B., Margolick, J. B., Sabundayo, B. P. and Schwartz, D. H., Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 2003. 362: 945950.
  • 46
    Geertsen, R., Hofbauer, G., Kamarashev, J., Yue, F. Y. and Dummer, R., Immune escape mechanisms in malignant melanoma. Int. J. Mol. Med. 1999. 3: 4957.
  • 47
    Walter, A., Barysch, M. J., Behnke, S., Dziunycz, P., Schmid, B., Ritter, E., Gnjatic, S., Kristiansen, G., Moch, H., Knuth, A., Dummer, R. and van den Broek, M., Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin. Cancer Res. 2010. 16: 35623570.